---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-24-000036"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:28:57.372115+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lifecore appoints Paul Josephs as CEO; concludes strategic review, remains standalone

## Summary
- Paul Josephs becomes President & CEO effective May 20, 2024, succeeding James Hall, who retires after 30+ years.
- Strategic review with 75+ buyers concluded; Board unanimously chose standalone execution.
- Josephs receives $550k base salary, 525k RSU (vest over 5 yrs), up to 1.5M PSU shares tied to stock price.
- Hall separation: $750k severance over 12 months, full equity vesting, COBRA premiums for 12 months.
- Craig Barbarosh not standing for reelection; Katrina Houde to become Board Chair at annual meeting.

## SEC filing metadata
- accession: 0001005286-24-000036
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000036/0001005286-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000036/lndc-20240320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-24-000036
- JSON: https://secwatch.observer/filing/0001005286-24-000036.json
- Plain text: https://secwatch.observer/filing/0001005286-24-000036.txt

## Key facts
- Executive change
  Paul Josephs was elected as President and Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.
  - Action: elected
  - Role: President and Chief Executive Officer
  source text: Paul Josephs has been elected as the Company’s President and Chief Executive Officer effective May 20, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000036/0001005286-24-000036-index.htm
- Executive change
  James G. Hall resigned as President and Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: Mr. Josephs will succeed James G. Hall, the Company’s current President and Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000036/0001005286-24-000036-index.htm
- Executive change
  Paul Josephs was elected as Director at LIFECORE BIOMEDICAL, INC. DE.
  - Action: elected
  - Role: Director
  source text: Mr. Josephs will be elected to the Board of Directors of the Company (the “Board”) to the vacancy caused by the resignation of Mr. Hall on the later of the Effective Date or the date of the Annual Meeting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000036/0001005286-24-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.